These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7912423)

  • 41. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Platinum compounds and paclitaxel in advanced epithelial ovarian cancer.
    Gadducci A; Brunetti I; Cosio S; Giannessi PG; Genazzani AR; Conte P
    Anticancer Res; 1997; 17(6D):4703-8. PubMed ID: 9494592
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
    Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
    Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Latest information in the diagnoses of ovarian carcinoma].
    Isonishi S
    Gan To Kagaku Ryoho; 2002 Aug; 29(8):1351-7. PubMed ID: 12214460
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
    Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
    Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer.
    Markman M
    Cancer J; 2009; 15(2):105-9. PubMed ID: 19390303
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma.
    McCreath WA; Eisenhauer EL; Abu-Rustum NR; Venkatraman ES; Caceres A; Bier R; Huh J; Cho J; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Jul; 102(1):8-14. PubMed ID: 16427689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First-line treatment of advanced ovarian cancer: current research and perspectives.
    Marchetti C; Pisano C; Facchini G; Bruni GS; Magazzino FP; Losito S; Pignata S
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):47-60. PubMed ID: 20014885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemotherapy for advanced epithelial ovarian cancer.
    Ozols RF
    Hematol Oncol Clin North Am; 1992 Aug; 6(4):879-94. PubMed ID: 1500391
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Current approaches in the medical treatment of advanced ovarian carcinoma].
    Aitini E; Cavazzini G; Cantore M; Rabbi C; Pari F; Mambrini A; Malavasi V; Smerieri F
    Recenti Prog Med; 1994 Dec; 85(12):587-90. PubMed ID: 7899684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ovarian cancer. Experimental chemotherapy.
    McGuire WP
    Hematol Oncol Clin North Am; 1992 Aug; 6(4):927-40. PubMed ID: 1500394
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New frontiers in ovarian cancer diagnosis and management.
    Barber HR
    Yale J Biol Med; 1991; 64(2):127-41. PubMed ID: 1721478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intraperitoneal chemotherapy for epithelial ovarian cancer.
    Alhayki M; Hopkins L; Le T
    Obstet Gynecol Surv; 2006 Aug; 61(8):529-34. PubMed ID: 16842633
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer.
    Seamon LG; Richardson DL; Copeland LJ
    Clin Obstet Gynecol; 2012 Mar; 55(1):131-55. PubMed ID: 22343234
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Promising new developments in the systemic treatment of ovarian cancer.
    Reed E
    J Assoc Acad Minor Phys; 1994; 5(1):16-21. PubMed ID: 7513218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.